Altered expression of wnt signaling pathway components in osteogenesis of mesenchymal stem cells in osteoarthritis patients

PLoS ONE

Volumn 10, Issue 9, 2015, Pages

  Tornero Esteban, Pilar ^a   Peralta Sastre, Ascensión ^a   Herranz, Eva ^a   Rodríguez Rodríguez, Luis ^a   Mucientes, Arkaitz ^a   Abásolo, Lydia ^a   Marco, Fernando ^a   Fernández Gutiérrez, Benjamín ^a   Lamas, José Ramón ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CALCIUM; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN TYROSINE KINASE; RNA; TRANSCRIPTION FACTOR; WNT PROTEIN; CELL SURFACE RECEPTOR; CTNNB1 PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; PROTEIN KINASE;

ADULT; AGED; ARTICLE; BONE DEVELOPMENT; CALCIUM METABOLISM; CELL EXPANSION; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME PHOSPHORYLATION; FEMALE; GENE EXPRESSION REGULATION; HOMEOSTASIS; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MESENCHYMAL STEM CELL; OSTEOARTHRITIS; PATHOPHYSIOLOGY; PROTEIN ANALYSIS; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; WNT SIGNALING PATHWAY; BONE MARROW; CELL CULTURE; CELL LINEAGE; CHONDROGENESIS; DRUG EFFECTS; GENETICS; MESENCHYMAL STROMA CELL; METABOLISM; MIDDLE AGED; PATHOLOGY; PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIGENS, CD; BETA CATENIN; BONE MARROW; CALCIUM; CELL LINEAGE; CELLS, CULTURED; CHONDROGENESIS; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MALE; MESENCHYMAL STROMAL CELLS; MIDDLE AGED; OSTEOARTHRITIS; OSTEOGENESIS; PHOSPHORYLATION; PROTEIN KINASES; PROTEIN PROCESSING, POST-TRANSLATIONAL; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, CELL SURFACE; TRANSCRIPTION FACTORS; WNT PROTEINS; WNT SIGNALING PATHWAY;

EID: 84944754754     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0137170     Document Type: Article

References (49)

1. Lajeunesse D, Reboul P. Subchondral bone in osteoarthritis: a biologic link with articular cartilage leading to abnormal remodeling. Curr Opin Rheumatol. 2003; 15(5):628-33. Epub 2003/09/10. PMID: 12960492.
2. Lories RJ, Luyten FP. The bone-cartilage unit in osteoarthritis. Nat Rev Rheumatol. 2011; 7(1):43-9. Epub 2010/12/08. doi: 10.1038/nrrheum.2010.197 PMID: 21135881.
3. Guilak F. Biomechanical factors in osteoarthritis. Best Pract Res Clin Rheumatol. 2011; 25(6):815-23. Epub 2012/01/24. doi: S1521-6942(11)00169-0 [pii] 10.1016/j.berh.2011.11.013. PMID: 22265263; PubMed Central PMCID: PMC3266544. doi: 10.1016/j.berh.2011.11.013
4. Chapman K, Valdes AM. Genetic factors in OA pathogenesis. Bone. 2012; 51(2):258-64. Epub 2011/12/20. doi: S8756-3282(11)01365-2 [pii] doi: 10.1016/j.bone.2011.11.026 PMID: 22178404.
5. KwanTat S, Lajeunesse D, Pelletier JP, Martel-Pelletier J. Targeting subchondral bone for treating osteoarthritis: what is the evidence? Best Pract Res Clin Rheumatol. 2010; 24(1):51-70. Epub 2010/02/05. doi: S1521-6942(09)00087-4 [pii] doi: 10.1016/j.berh.2009.08.004 PMID: 20129200.
6. Dequeker J, Aerssens J, Luyten FP. Osteoarthritis and osteoporosis: clinical and research evidence of inverse relationship. Aging Clin Exp Res. 2003; 15(5):426-39. Epub 2004/01/02. PMID: 14703009.
7. Hardcastle SA, Gregson CL, Deere KC, Davey Smith G, Dieppe P, Tobias JH. High bone mass is associated with an increased prevalence of joint replacement: a case-control study. Rheumatology (Oxford). 2013; 52(6):1042-51. Epub 2013/01/31. doi: kes411 [pii] doi: 10.1093/rheumatology/kes411 PMID: 23362220; PubMed Central PMCID: PMC3651613.
8. Gupta PK, Das AK, Chullikana A, Majumdar AS. Mesenchymal stem cells for cartilage repair in osteoarthritis. Stem Cell Res Ther. 2012; 3(4):25. Epub 2012/07/11. doi: 10.1186/scrt116 PMID: 22776206.
9. Mak KK, Bi Y, Wan C, Chuang PT, Clemens T, Young M, et al. Hedgehog signaling in mature osteoblasts regulates bone formation and resorption by controlling PTHrP and RANKL expression. Developmental cell. 2008; 14(5):674-88. Epub 2008/05/15. doi: S1534-5807(08)00073-7 [pii] doi: 10.1016/j.devcel.2008.02.003 PMID: 18477451.
10. Kawaguchi H. Regulation of osteoarthritis development by Wnt-beta-catenin signaling through the endochondral ossification process. Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research. 2009; 24(1):8-11. Epub 2008/11/20. doi: 10.1359/jbmr.081115 PMID: 19016582.
11. Corr M. Wnt-beta-catenin signaling in the pathogenesis of osteoarthritis. Nature clinical practice Rheumatology. 2008; 4(10):550-6. Epub 2008/09/30. doi: ncprheum0904 [pii] doi: 10.1038/ncprheum0904 PMID: 18820702.
12. Baron R, Kneissel M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med. 2013; 19(2):179-92. Epub 2013/02/08. doi: 10.1038/nm.3074 PMID: 23389618.
13. Corr M. Wnt-beta-catenin signaling in the pathogenesis of osteoarthritis. Nat Clin Pract Rheumatol. 2008; 4(10):550-6. Epub 2008/09/30. doi: ncprheum0904 [pii] doi: 10.1038/ncprheum0904 PMID: 18820702.
14. Yavropoulou MP, Yovos JG. The role of the Wnt signaling pathway in osteoblast commitment and differentiation. Hormones (Athens). 2007; 6(4):279-94. Epub 2007/12/07. PMID: 18055419.
15. De A. Wnt/Ca2+ signaling pathway: abrief overview. Acta Biochim Biophys Sin (Shanghai). 2011; 43(10):745-56. Epub 2011/09/10. doi: 10.1093/abbs/gmr079 PMID: 21903638.
16. Buechling T, Boutros M. Wnt signaling signaling at and above the receptor level. Curr Top Dev Biol. 2011; 97:21-53. Epub 2011/11/15. doi: 10.1016/B978-0-12-385975-4.00008-5 PMID: 22074601.
17. Kim JA, Kang YJ, Park G, Kim M, Park YO, Kim H, et al. Identification of a stroma-mediated Wnt/beta-catenin signal promoting self-renewal of hematopoietic stem cells in the stem cell niche. Stem Cells. 2009; 27(6):1318-29. Epub 2009/06/03. doi: 10.1002/stem.52 PMID: 19489023.
18. Blank U, Karlsson G, Karlsson S. Signaling pathways governing stem-cell fate. Blood. 2008; 111(2):492-503. Epub 2007/10/05. doi: 10.1182/blood-2007-07-075168 PMID: 17914027.
19. Suda T, Arai F. Wnt signaling in the niche. Cell. 2008; 132(5):729-30. Epub 2008/03/11. doi: 10.1016/j.cell.2008.02.017 PMID: 18329358.
20. Ling L, Nurcombe V, Cool SM. Wnt signaling controls the fate of mesenchymal stem cells. Gene. 2009; 433(1-2):1-7. Epub 2009/01/13. doi: 10.1016/j.gene.2008.12.008 PMID: 19135507.
21. MacFarlane RJ, Graham SM, Davies PS, Korres N, Tsouchnica H, Heliotis M, et al. Anti-inflammatory role and immunomodulation of mesenchymal stem cells in systemic joint diseases: potential for treatment. Expert Opin Ther Targets. 2013; 17(3):243-54. Epub 2013/01/09. doi: 10.1517/14728222.2013.746954 PMID: 23293906.
22. Stagg J, Galipeau J. Mechanisms of immune modulation by mesenchymal stromal cells and clinical translation. Curr Mol Med. 2013; 13(5):856-67. Epub 2013/05/07. doi: CMM-EPUB-20130502-15 [pii]. PMID: 23642066.
23. Lories RJ. Joint homeostasis, restoration, and remodeling in osteoarthritis. Best Pract Res Clin Rheumatol. 2008; 22(2):209-20. Epub 2008/05/06. doi: S1521-6942(07)00134-9 [pii] doi: 10.1016/j.berh.2007.12.001 PMID: 18455680.
24. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006; 8(4):315-7. doi: 10.1080/14653240600855905 PMID: 16923606.
25. Mikels AJ, Nusse R. Purified Wnt5a protein activates or inhibits beta-catenin-TCF signaling depending on receptor context. PLoS Biol. 2006; 4(4):e115. Epub 2006/04/11. doi: 05-PLBI-RA-1339R3 [pii] doi: 10.1371/journal.pbio.0040115 PMID: 16602827; PubMed Central PMCID: PMC1420652.
26. Yuan Y, Niu CC, Deng G, Li ZQ, Pan J, Zhao C, et al. The Wnt5a/Ror2 noncanonical signaling pathway inhibits canonical Wnt signaling in K562 cells. International journal of molecular medicine. 2011; 27(1):63-9. Epub 2010/11/12. doi: 10.3892/ijmm.2010.560 PMID: 21069266.
27. Maeda K, Kobayashi Y, Udagawa N, Uehara S, Ishihara A, Mizoguchi T, et al. Wnt5a-Ror2 signaling between osteoblast-lineage cells and osteoclast precursors enhances osteoclastogenesis. Nat Med. 2012; 18(3):405-12. Epub 2012/02/22. doi: nm.2653 [pii] doi: 10.1038/nm.2653 PMID: 22344299.
28. Person AD, Beiraghi S, Sieben CM, Hermanson S, Neumann AN, Robu ME, et al. WNT5A mutations in patients with autosomal dominant Robinow syndrome. Dev Dyn. 2010; 239(1):327-37. Epub 2009/11/18. doi: 10.1002/dvdy.22156 PMID: 19918918.
29. Hsieh JC, Rattner A, Smallwood PM, Nathans J. Biochemical characterization of Wnt-frizzled interactions using a soluble, biologically active vertebrate Wnt protein. Proc Natl Acad Sci USA. 1999; 96(7):3546-51. Epub 1999/03/31. PMID: 10097073; PubMed Central PMCID: PMC22330.
30. Westendorf JJ, Kahler RA, Schroeder TM. Wnt signaling in osteoblasts and bone diseases. Gene. 2004; 341:19-39. Epub 2004/10/12. doi: S0378-1119(04)00385-3 [pii] doi: 10.1016/j.gene.2004.06.044 PMID: 15474285.
31. Golan T, Yaniv A, Bafico A, Liu G, Gazit A. The human Frizzled 6 (HFz6) acts as a negative regulator of the canonical Wnt. beta-catenin signaling cascade. J Biol Chem. 2004; 279(15):14879-88. Epub 2004/01/30. doi: 10.1074/jbc.M306421200 M306421200 [pii]. PMID: 14747478.
32. Korvala J, Juppner H, Makitie O, Sochett E, Schnabel D, Mora S, et al. Mutations in LRP5cause primary osteoporosis without features of OI by reducing Wnt signaling activity. BMC Med Genet. 2012; 13:26. Epub 2012/04/11. doi: 1471-2350-13-26 [pii] doi: 10.1186/1471-2350-13-26 PMID: 22487062; PubMed Central PMCID: PMC3374890.
33. Van Wesenbeeck L, Cleiren E, Gram J, Beals RK, Benichou O, Scopelliti D, et al. Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density. Am J Hum Genet. 2003; 72(3):763-71. Epub 2003/02/13. doi: S0002-9297(07)60594-1 [pii] doi: 10.1086/368277 PMID: 12579474; PubMed Central PMCID: PMC1180253.
34. Bhat BM, Allen KM, Liu W, Graham J, Morales A, Anisowicz A, et al. Structure-based mutation analysis shows the importance of LRP5 beta-propeller 1 in modulating Dkk1-mediated inhibition of Wnt signaling. Gene. 2007; 391(1-2):103-12. Epub 2007/02/06. doi: S0378-1119(06)00767-0 [pii] doi: 10.1016/j.gene.2006.12.014 PMID: 17276019.
35. Pangrazio A, Boudin E, Piters E, Damante G, Lo Iacono N, D'Elia AV, et al. Identification of the first deletion in the LRP5genein a patient with autosomal dominant osteopetrosis type I. Bone. 2011; 49(3):568-71. Epub 2011/05/24. doi: S8756-3282(11)00980-X [pii] doi: 10.1016/j.bone.2011.05.006 PMID: 21600326; PubMed Central PMCID: PMC3149657.
36. Balemans W, Devogelaer JP, Cleiren E, Piters E, Caussin E, Van Hul W. Novel LRP5 missense mutation in a patient with a high bone mass phenotype results in decreased DKK1-mediated inhibition of Wnt signaling. J Bone Miner Res. 2007; 22(5):708-16. Epub 2007/02/14. doi: 10.1359/jbmr.070211 PMID: 17295608.
37. Bernatik O, Ganji RS, Dijksterhuis JP, Konik P, Cervenka I, Polonio T, et al. Sequential activation and inactivation of Dishevelled in the Wnt/beta-catenin pathway by casein kinases. J Biol Chem. 2011; 286(12):10396-410. Epub 2011/02/03. doi: M110.169870 [pii] doi: 10.1074/jbc.M110.169870 PMID: 21285348; PubMed Central PMCID: PMC3060493.
38. Gao Y, Wang HY. Casein kinase 2 Is activated and essential for Wnt/beta-catenin signaling. J Biol Chem. 2006; 281(27):18394-400. Epub 2006/05/05. doi: M601112200 [pii] doi: 10.1074/jbc.M601112200 PMID: 16672224.
39. Mills CN, Nowsheen S, Bonner JA, Yang ES. Emerging roles of glycogen synthase kinase 3 in the treatment of brain tumors. Front Mol Neurosci. 2011; 4:47. Epub 2012/01/26. doi: 10.3389/fnmol.2011.00047 PMID: 22275880; PubMed Central PMCID: PMC3223722.
40. Amit S, Hatzubai A, Birman Y, Andersen JS, Ben-Shushan E, Mann M, et al. Axin-mediated CKI phosphorylation of beta-catenin at Ser 45: a molecular switch for the Wnt pathway. Genes Dev. 2002; 16(9):1066-76. Epub 2002/05/10. doi: 10.1101/gad.230302 PMID: 12000790; PubMed Central PMCID: PMC186245.
41. Artigas N, Urena C, Rodriguez-Carballo E, Rosa JL, Ventura F. Mitogen activated protein kinase (MAPK)-regulated Interactions between Osterix and Runx2 Are Critical for the Transcriptional Osteogenic Program. J Biol Chem. 2014. Epub 2014/08/15. doi: M114.576793 [pii] doi: 10.1074/jbc.M114.576793 PMID: 25122769.
42. Prasadam I, Crawford R, Xiao Y. Aggravation of ADAMTS and matrix metalloproteinase production and role of ERK1/2 pathway in the interaction of osteoarthritic subchondral bone osteoblasts and articular cartilage chondrocytes-possible pathogenic role in osteoarthritis. The Journal of rheumatology. 2012; 39(3):621-34. Epub 2012/01/17. doi: jrheum.110777 [pii] doi: 10.3899/jrheum.110777 PMID: 22247346.
43. Greenblatt MB, Shim JH, Glimcher LH. Mitogen-activated protein kinase pathways in osteoblasts. Annu Rev Cell Dev Biol. 2013; 29:63-79. Epub 2013/06/04. doi: 10.1146/annurev-cellbio-101512-122347 PMID: 23725048.
44. Shui C, Spelsberg TC, Riggs BL, Khosla S. Changes in Runx2/Cbfa1 expression and activity during osteoblastic differentiation of human bone marrow stromal cells. Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research. 2003; 18(2):213-21. Epub 2003/02/06. doi: 10.1359/jbmr.2003.18.2.213 PMID: 12568398.
45. Zhang J, Tu Q, Bonewald LF, He X, Stein G, Lian J, et al. Effects of miR-335-5p in modulating osteogenic differentiation by specifically downregulating Wnt antagonist DKK1. Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research. 2011; 26(8):1953-63. Epub 2011/02/26. doi: 10.1002/jbmr.377 PMID: 21351149; PubMed Central PMCID: PMC3810406.
46. Lories RJ, Corr M, Lane NE. To Wnt or not to Wnt: the bone and joint health dilemma. Nat Rev Rheumatol. 2013; 9(6):328-39. Epub 2013/03/06. doi: nrrheum.2013.25 [pii] doi: 10.1038/nrrheum.2013.25 PMID: 23459013.
47. Lories RJ, Luyten FP, de Vlam K. Progress in spondylarthritis. Mechanisms of new bone formation in spondylarthritis. Arthritis Res Ther. 2009; 11(2):221. Epub 2009/05/15. doi: ar2642[pii] doi: 10.1186/ar2642 PMID: 19439035; PubMed Central PMCID: PMC2688182.
48. Boyden LM, Mao J, Belsky J, Mitzner L, Farhi A, Mitnick MA, et al. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med. 2002; 346(20):1513-21. Epub 2002/05/17. doi: 10.1056/NEJMoa013444346/20/1513 [pii]. PMID: 12015390.
49. Uitterlinden AG, Arp PP, Paeper BW, Charmley P, Proll S, Rivadeneira F, et al. Polymorphisms in the sclerosteosis/van Buchem disease gene (SOST) region are associated with bone-mineral density in elderly whites. Am J Hum Genet. 2004; 75(6):1032-45. Epub 2004/10/30. doi: S0002-9297(07)60071-8 [pii] doi: 10.1086/426458 PMID: 15514891; PubMed Central PMCID: PMC1182139.